Cancer Institute A national cancer institute
designated cancer center

Tumor Heterogeneity: Implications for Targeted Therapy

October 6 - 7, 2014
Li Ka Shing Center for Learning & Knowledge

Sponsored by the Stanford Cancer Institute

Monday, October 6 : Morning Session

Welcome

Beverly Mitchell, Professor of Medicine, Director, Stanford Cancer Institute

Overview

Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute

Keynote   

Breast Tumor Heterogeneity
Kornelia Polyak, Professor, Department of Medicine, Harvard Medical School

Panel        

How precisely can we measure and interpretintra-patient tumor heterogeneity?                   

  • David Haussler, Distinguished Professor of Biomolecular Engineering, University of California, Santa Cruz
  • Gary Nolan, Professor of Microbiology and Immunology, Stanford University
  • Steven Quake, Professor of Bioengineering, Stanford University

Tuesday, October 7 : Morning Session

Keynote:

Can An Evolutionary and Ecological Perspective Bring New Insights into the Heterogeneity Issue?
Carlo Maley, Assoc. Professor, Department of Surgery, Director, Center for Evolution and Cancer, University of California, San Francisco.

Panel 

How will transcriptomic, microenvironmental andproteomic heterogeneity affect therapeutic strategies?

  • Megan Hitchins, Assoc. Professor of Medicine, Stanford University
  • Mina Bissell, Distinguished Scientist, Lawrence Berkeley National Laboratory
  • Kimberly Allison, Assoc. Professor of Pathology, Stanford University
  • Amato Giaccia (moderator), Professor of Radiation Oncology, Assoc. Director for Basic Science, Stanford Cancer Institute

Poster Review:  Amato Giaccia

Monday, October 6 : Afternoon Session

Keynote   

Understanding the Cancer Genome
Kenneth Kinzler, Professor of Oncology, Johns Hopkins University

Panel          

Are immune therapies superior to other targeted therapies in treating heterogeneous tumors?

  • Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute
  • Ash Alizadeh, Assistant Professor of Medicine, Stanford University
  • Paul Robbins (moderator), Staff Scientist, National Cancer Institute

Short Talk

How should concerns about heterogeneity affect current and future clinical practice?
George Sledge, Professor of Medicine, Stanford University

Short Talk

How does the stem cell theory of cancer development affect concerns about intra-patient tumor heterogeneity?
Irving Weissman, Professor of Developmental Biology, Director Stanford Institute for Stem Cell Biology and Regenerative Medicine

Tuesday, October 7 : Afternoon Session

Keynote   

Spatial and Temporal Heterogeneity in Solid Tumors:Implications for Trial Design 
Charles Swanton, Professor, Cancer Research UK, London Research Institute

Panel                    

Implications of intra-patient heterogeneity fordiagnostics, treatment, and monitoring response.

  • Andrei Iagaru, Assistant Professor of Radiology, Stanford University
  • Matt van de Rijn, Professor of Pathology, Stanford University
  • Maximillian Diehn, Assistant Professor of Medicine, Stanford University
  • R. West (moderator), Associate Professor of Pathology, Stanford University

Panel        

How should intra-patient heterogeneity affect thedesign of clinical trials?

  • Mark Pegram, Professor of Medicine, Assoc. Director for Clinical Research, Stanford Cancer Institute
  • Joel Neal, Assistant Professor of Medicine, Stanford University
  • Charles Swanton (moderator), Professor, Cancer Research UK, London Research Institute

Wrap-up

What Have We Learned? What Do We Need to Learn?

  • Beverly Mitchell, Professor of Medicine, Director, Stanford Cancer Institute
  • Ron Levy, Professor of Medicine, Assoc. Director for Translational Research, Stanford Cancer Institute
  • All Keynote Speakers

 

 

 

 

 

 


 

Stanford Medicine Resources:

Footer Links: